Oramed (ORMP) Submits Pre-IND Request to FDA for Oral Exenatide Capsule

JERUSALEM, July 30, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that it submitted a pre-Investigational New Drug (pre-IND) meeting request to the U.S. Food and Drug Administration (FDA) for a US-based trial on its orally ingestible exenatide capsule, ORMD-0901.

Nadav Kidron, CEO of Oramed, commented, “We are very pleased to have submitted this pre-IND meeting request letter as part of our efforts to advance ORMD-0901 into US clinical trials. We look forward to the FDA’s response and preparing ourselves accordingly in our efforts leading up to full IND submission on our second product.”
About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit www.oramed.com.

Implant Sciences (IMSC) Moves Into 58,000 Sq Ft Manufacturing Facility

WILMINGTON, MA–(Marketwired – Jul 30, 2013) – Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that it has moved its headquarters and manufacturing operations to 500 Research Drive Unit 3, Wilmington, Massachusetts 01887. The new 58,000 square foot facility, located in the same technology park as its prior location, offers the Company more than double its previous space. Implant Sciences’ telephone and fax numbers remain the same, phone: 978-752-1700, fax: 978-752-1711.

“As we continue to advance our certification efforts both here in the U.S. and internationally, we expect growing sales. Expanding our Massachusetts facility underscores our commitment to manufacturing high-tech equipment right here in the USA,” stated Implant Sciences’ President and CEO Glenn D. Bolduc. “I’m very proud of everything the entire Implant Sciences team has accomplished to bring us to this point, and look forward to continued growth in the future.”
Brenda Baron, Vice President of Manufacturing for Implant Sciences, added, “In FY2013, Implant Sciences built and shipped more units than ever before in its history. I’m very proud of what the manufacturing team was able to accomplish. This new facility is critical to supporting continued growth in sales.” “Since manufacturing requirements were paramount in our need for a new facility, Brenda was in charge of planning and executing the move,” added Dr. William McGann, Chief Operations Officer for Implant Sciences. “She and her team did an amazing job, relocating all of Implant Sciences with minimal downtime.”

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences’ QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company’s QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company’s website at www.implantsciences.com.